Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.79 USD
-0.02 (-1.10%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $1.77 -0.02 (-1.12%) 7:50 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 6 |
Average Target Price | $24.74 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 78 of 252 |
Current Quarter EPS Est: | -2.03 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 7 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/9/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
3/19/2024 | Alliance Global Partners | Research Department | Not Available | Strong Buy |
3/15/2024 | The Benchmark Company | Robert Wasserman | Strong Buy | Strong Buy |
3/15/2024 | Roth Capital Partners | Jason Wittes | Not Available | Strong Buy |
8/15/2023 | Cantor Fitzgerald & Co | Jennifer Kim | Strong Buy | Strong Buy |
7/17/2023 | B. Riley Securities | Mayank Mamtani | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.